Teva Pharmaceutical Industries (TEVA) Asset Writedowns and Impairment (2016 - 2024)
Historic Asset Writedowns and Impairment for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Q1 2024 value amounting to $679.0 million.
- Teva Pharmaceutical Industries' Asset Writedowns and Impairment rose 25925.93% to $679.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $869.0 million, marking a year-over-year decrease of 6484.63%. This contributed to the annual value of $1.0 billion for FY2025, which is 1937.25% down from last year.
- Teva Pharmaceutical Industries' Asset Writedowns and Impairment amounted to $679.0 million in Q1 2024, which was up 25925.93% from -$632.0 million recorded in Q4 2023.
- Teva Pharmaceutical Industries' 5-year Asset Writedowns and Impairment high stood at $5.2 billion for Q3 2020, and its period low was -$632.0 million during Q4 2023.
- Over the past 5 years, Teva Pharmaceutical Industries' median Asset Writedowns and Impairment value was $227.0 million (recorded in 2021), while the average stood at $625.6 million.
- Per our database at Business Quant, Teva Pharmaceutical Industries' Asset Writedowns and Impairment surged by 243365.85% in 2020 and then tumbled by 14373.7% in 2023.
- Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Asset Writedowns and Impairment stood at $232.0 million in 2020, then decreased by 21.12% to $183.0 million in 2021, then soared by 689.62% to $1.4 billion in 2022, then plummeted by 143.74% to -$632.0 million in 2023, then skyrocketed by 207.44% to $679.0 million in 2024.
- Its Asset Writedowns and Impairment was $679.0 million in Q1 2024, compared to -$632.0 million in Q4 2023 and $48.0 million in Q3 2023.